GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sinco Pharmaceutical Holdings Ltd (HKSE:06833) » Definitions » Capex-to-Operating-Income

Sinco Pharmaceutical Holdings (HKSE:06833) Capex-to-Operating-Income : 0.28 (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Sinco Pharmaceutical Holdings Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Sinco Pharmaceutical Holdings's Capital Expenditure for the six months ended in Dec. 2023 was HK$-18.43 Mil. Its Operating Income for the six months ended in Dec. 2023 was HK$66.45 Mil.

Hence, Sinco Pharmaceutical Holdings's Capex-to-Operating-Income for the six months ended in Dec. 2023 was 0.28.


Sinco Pharmaceutical Holdings Capex-to-Operating-Income Historical Data

The historical data trend for Sinco Pharmaceutical Holdings's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinco Pharmaceutical Holdings Capex-to-Operating-Income Chart

Sinco Pharmaceutical Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.34 0.12 0.52 0.55

Sinco Pharmaceutical Holdings Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.24 0.26 2.13 0.84 0.28

Competitive Comparison of Sinco Pharmaceutical Holdings's Capex-to-Operating-Income

For the Medical Distribution subindustry, Sinco Pharmaceutical Holdings's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sinco Pharmaceutical Holdings's Capex-to-Operating-Income Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Sinco Pharmaceutical Holdings's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Sinco Pharmaceutical Holdings's Capex-to-Operating-Income falls into.



Sinco Pharmaceutical Holdings Capex-to-Operating-Income Calculation

Sinco Pharmaceutical Holdings's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-70.594) / 128.824
=0.55

Sinco Pharmaceutical Holdings's Capex-to-Operating-Income for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-18.427) / 66.448
=0.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sinco Pharmaceutical Holdings  (HKSE:06833) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Sinco Pharmaceutical Holdings Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Sinco Pharmaceutical Holdings's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Sinco Pharmaceutical Holdings (HKSE:06833) Business Description

Traded in Other Exchanges
N/A
Address
No. 1700, North Section of Tianfu Avenue, E5-1805, Global Centre, High-Tech Zone, Chengdu, Sichuan Province, Chengdu, CHN
Sinco Pharmaceutical Holdings Ltd is an investment holding company engaged in the provision of comprehensive marketing, promotion, and channel management service for imported pharmaceutical products and medical devices in China. The company has three operating segments; the sale of imported pharmaceutical products segment, the research and manufacturing of aesthetic medicine segment, and the medical beauty services segment. Its product offering includes Human albumin solutions and Antibiotics like Axetine and Medocef.
Executives
Huang Zhijian 2305 Beneficiary of a trust
Fullwealth Holdings Limited 2201 Interest of corporation controlled by you
Risun Investments Limited 2101 Beneficial owner
Wickhams Cay Trust Company Limited 2301 Trustee
Huang Xiangbin 2307 Founder of a discretionary trust who can infl

Sinco Pharmaceutical Holdings (HKSE:06833) Headlines

No Headlines